Reference manuals

J. Starp, A. Leonhardt, M. Zoller, C. Scharf, J. Zander, M. Paal, S. Greppmair, L.M. Schatz, J. Ermtraud, A.K. Kunzelmann, C. König, J. Grensemann, L. Reiter, C. Lau, D. Marriott, S.L. Stocker, S.G. Wicha, U. Liebchen; PK/PD Study Group of the European Society of Clinical Microbiology and Infectious Diseases (EPASG)

Towards model-informed precision dosing of intravenous linezolid: a multicentre external evaluation of pharmacokinetic models in critically ill adults.

Clin. Microbiol. Infect. 32: 80–86 (2026). · doi:10.1016/j.cmi.2025.08.032

E.-M.A. Wansing, E. Behrens, N.M. Kröger, C. Langebrake, S.G. Wicha

Towards precision dosing of vancomycin in patients with allogeneic hematopoietic stem cell transplantation: a comparison of published population pharmacokinetic models.

Antimicrob. Agents Chemother. 69: e0025725 (2025). · doi:10.1128/aac.00257-25

I.K. Minichmayr, E. Dreesen, M. Centanni, Z. Wang, Y. Hoffert, L.E. Friberg, S.G. Wicha

Model-informed precision dosing: State of the art and future perspectives.

Adv. Drug Deliv. Rev. 215: 115421 (2024). · doi:10.1016/j.addr.2024.115421

L.M. Schatz, S. Greppmair, A.K. Kunzelmann, J. Starp, A. Brinkmann, A. Roehr, O. Frey, S. Hagel, C. Dorn, M. Zoller, C. Scharf, S.G. Wicha, U. Liebchen

Predictive performance of multi-model approaches for model-informed precision dosing of piperacillin in critically ill patients.

Int. J. Antimicrob. Agents. 64: 107305 (2024). · doi:10.1016/j.ijantimicag.2024.107305

D. Alsoud, D.J.A.R. Moes, Z. Wang, R. Soenen, Z. Layegh, M. Barclay, T. Mizuno, I.K. Minichmayr, R.J. Keizer, S.G. Wicha, G. Wolbink, J. Lambert, S. Vermeire, A. de Vries, K. Papamichael, N. Padullés-Zamora, E. Dreesen

Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.

Ther. Drug Monit. 46: 291–308 (2024). · doi:10.1097/FTD.0000000000001204

S. Greppmair, A. Brinkmann, A. Roehr, O. Frey, S. Hagel, C. Dorn, A. Marsot, I. El-Haffaf, M. Zoller, T. Saller, J. Zander, L.M. Schatz, C. Scharf, J. Briegel, I.K. Minichmayr, S.G. Wicha, U. Liebchen

Towards model-informed precision dosing of piperacillin: multicenter systematic external evaluation of pharmacokinetic models in critically ill adults with a focus on Bayesian forecasting.

Intensive Care Med. 49: 966–976 (2023). · doi:10.1007/s00134-023-07154-0

W. Kantasiripitak, S.G. Wicha, D. Thomas, I. Hoffman, M. Ferrante, S. Vermeire, K. van Hoeve, E. Dreesen

A model-based tool for guiding infliximab induction dosing to maximise long-term deep remission in children with inflammatory bowel diseases.

J. Crohns Colitis. (2023). · doi:10.1093/ecco-jcc/jjad009

D.W. Uster, P. Chowdary, A. Riddell, C. Garcia, E. Aradom, M. Musarara, S.G. Wicha

Dosing for Personalized Prophylaxis in Hemophilia A highly varies on the underlying Population Pharmacokinetic Models.

Ther. Drug Monit. 44: 665–673 (2022). · doi:10.1097/FTD.0000000000000983

W. Kantasiripitak, A. Outtier, S.G. Wicha, A. Kensert, Z. Wang, J. Sabino, S. Vermeire, D. Thomas, M. Ferrante, E. Dreesen

Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases.

CPT Pharmacometrics Syst. Pharmacol. 11: 1045–1059 (2022). · doi:10.1002/psp4.12813

H. Gastmans, E. Dreesen, S.G. Wicha, N. Dia, E. Spreuwers, A. Dompas, K. Allegaert, S. Desmet, K. Lagrou, W.E. Peetermans, Y. Debaveye, I. Spriet, M. Gijsen

Systematic Comparison of Hospital-Wide Standard and Model-Based Therapeutic Drug Monitoring of Vancomycin in Adults.

Pharmaceutics. 14: 1459 (2022). · doi:10.3390/pharmaceutics14071459

A. Heus, D.W. Uster, V. Grootaert, N. Vermeulen, A. Somers, D.H. In't Veld, S.G. Wicha, P.A. De Cock

Model-informed precision dosing of vancomycin via continuous infusion: a clinical fit-for-purpose evaluation of published PK models.

Int. J. Antimicrob. Agents. 59: 106579 (2022). · doi:10.1016/j.ijantimicag.2022.106579

D.W. Uster, S.G. Wicha

Optimized sampling to estimate vancomycin drug exposure: comparison of pharmacometric and equation-based approaches in a simulation-estimation study.

CPT Pharmacometrics Syst. Pharmacol. 11: 711–720 (2022). · doi:10.1002/psp4.12782

S.G. Wicha, A.G. Märtson, E.I. Nielsen, B.C.P. Koch, L.E. Friberg, J.W. Alffenaar, I.K. Minichmayr

From Therapeutic Drug Monitoring to Model-Informed Precision Dosing for Antibiotics.

Clin. Pharmacol. Ther. 109: 928–941 (2021). · doi:10.1002/cpt.2202

D.W. Uster, S.L. Stocker, J.E. Carland, J. Brett, D.J.E. Marriott, R.O. Day, S.G. Wicha

A Model Averaging/Selection Approach Improves the Predictive Performance of Model-Informed Precision Dosing: Vancomycin as a Case Study.

Clin. Pharmacol. Ther. 109: 175–183 (2021). · doi:10.1002/cpt.2065

C.B. Cunio, D.W. Uster, J.E. Carland, H. Buscher, Z. Liu, J. Brett, M. Stefani, G.R.D. Jones, R.O. Day, S.G. Wicha, S.L. Stocker

Towards precision dosing of vancomycin in critically ill patients: An evaluation of the predictive performance of pharmacometric models in ICU patients.

Clin. Microbiol. Infect. (2020). · doi:10.1016/j.cmi.2020.07.005

A. Broeker, M. Nardecchia, K.P. Klinker, H. Derendorf, R.O. Day, D.J. Marriott, J.E. Carland, S.L. Stocker, S.G. Wicha

Towards precision dosing of vancomycin: A systematic evaluation of pharmacometric models for Bayesian forecasting.

Clin. Microbiol. Infect. 25: 1286.e1–e7 (2019). · doi:10.1016/j.cmi.2019.02.029

M.A. Barras, D. Serisier, S. Hennig, K. Jess, R.L.G. Norris

Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis.

Antimicrob. Agents Chemother. 60: 6698–6702 (2016). · doi:10.1128/AAC.01131-16

S.G. Wicha, M.G. Kees, A. Solms, I.K. Minichmayr, A. Kratzer, C. Kloft

TDMx – a novel web-based open-access support tool for optimising antimicrobial dosing regimens in clinical routine.

Int. J. Antimicrob. Agents. 45: 442–444 (2015). · doi:10.1016/j.ijantimicag.2014.12.010